Q-omics provides the consensus-scored CECR3 profile across patient tissues and cancer cell-line models. CECR3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CECR3 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, CECR3 RNA expression shows 10,518 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight PAAD, KICH, and GBM as cancer lineages where CECR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CECR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CECR3 survival associations across molecular data types. CECR3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CECR3 RNA expression–survival associations across cancer types. High CECR3 expression shows unfavorable associations in THCA and ACC, but favorable associations in PAAD, UCS, KIRC and CHOL. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for CECR3 RNA expression.
This table summarizes CECR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CECR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CECR3 shows lower tumor expression in KICH, LUSC and THCA and higher tumor expression in KIRC, LIHC and KIRP. The KICH box plot shows higher CECR3 RNA expression in normal versus tumor tissue (log2 FC = −0.187, t-test p < 0.001).
This table shows molecular features associated with CECR3 in patient tissues and cancer cell lines. In patient samples, CECR3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
